Western Australia Atropine for the Treatment of Myopia (WA-ATOM) study: Rationale, methodology and participant baseline characteristics.

Autor: Lee SSY; Centre for Ophthalmology and Visual Sciences (incorporating Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia., Mackey DA; Centre for Ophthalmology and Visual Sciences (incorporating Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia.; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Victoria, Australia.; School of Medicine, Menzies Research Institute Tasmania, University of Tasmania, TAS, Australia., Lingham G; Centre for Ophthalmology and Visual Sciences (incorporating Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia., Crewe JM; Centre for Ophthalmology and Visual Sciences (incorporating Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia., Richards MD; Centre for Ophthalmology and Visual Sciences (incorporating Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia.; Department of Ophthalmology, Max Rady College of Medicine, University of Manitoba, Canada., Chen FK; Centre for Ophthalmology and Visual Sciences (incorporating Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia.; Department of Ophthalmology, Royal Perth Hospital, Perth, Western Australia, Australia., Charng J; Centre for Ophthalmology and Visual Sciences (incorporating Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia., Ng F; Centre for Ophthalmology and Visual Sciences (incorporating Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia., Flitcroft I; Department of Ophthalmology, Mater Misericordiae University Hospital, Dublin, Ireland., Loughman JJ; Centre for Eye Research Ireland, School of Physics, Clinical and Optometric Sciences, Technological University Dublin, Dublin, Ireland., Azuara-Blanco A; School of Medicine Dentistry, and Biomedical Science, Queen's University Belfast, Ireland., Logan NS; School of Life & Health Sciences, Aston University, Birmingham, UK., Hammond CJ; Department of Twin Research and Genetic Epidemiology, King's College London, St. Thomas' Hospital, London, UK., Chia A; Singapore National Eye Centre, Singapore.; Singapore Eye Research Institute, Singapore., Truong TT; Oxford Compounding, North Perth, Western Australia, Australia., Clark A; Centre for Ophthalmology and Visual Sciences (incorporating Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia.
Jazyk: angličtina
Zdroj: Clinical & experimental ophthalmology [Clin Exp Ophthalmol] 2020 Jul; Vol. 48 (5), pp. 569-579. Date of Electronic Publication: 2020 Apr 01.
DOI: 10.1111/ceo.13736
Abstrakt: Importance: Atropine eyedrops are a promising treatment for slowing myopia progression in East Asian children. However, its effects on children in Australia, including those of non-Asian background, have not been well-studied.
Background: The Western Australia Atropine for the Treatment of Myopia (WA-ATOM) study aims to determine the efficacy and long-term effects of low-dose atropine eyedrops in myopia control. This paper describes the study rationale, methodology and participant baseline characteristics.
Design: Single-centre, double-masked, randomized controlled trial.
Participants: Children (6-16 years) with spherical equivalent ≤-1.50 D in each eye, astigmatism ≤1.50 D and myopia progression by ≥0.50 D/year.
Methods: Enrolled children were randomly assigned 2:1 to receive 0.01% atropine or placebo eyedrops. Participants are examined every 6 months during first 3 years of the study (2-year treatment phase followed by a 1-year washout phase), and then at a 5-year follow-up (2 years after the end of the washout phase).
Main Outcome Measures: Annual progression rate of myopia and axial length, tolerability to eyedrops and incidence and severity of unwanted effects.
Results: Out of 311 children who were referred, 242 were suitable for study participation, and 153 were subsequently enrolled. The baseline characteristics of enrolled participants are presented.
Conclusions and Relevance: Outcomes of the WA-ATOM study will inform on the efficacy, tolerability, safety and long-term effects of low-dose atropine eyedrops in myopia control in Australian children. The impact of ocular sun exposure, iris colour and parental myopia on the efficacy of low-dose atropine will also be assessed.
(© 2020 Royal Australian and New Zealand College of Ophthalmologists.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje